收费全文 | 1268551篇 |
免费 | 96448篇 |
国内免费 | 1547篇 |
耳鼻咽喉 | 16474篇 |
儿科学 | 41300篇 |
妇产科学 | 35174篇 |
基础医学 | 189843篇 |
口腔科学 | 34936篇 |
临床医学 | 118364篇 |
内科学 | 247203篇 |
皮肤病学 | 27499篇 |
神经病学 | 102407篇 |
特种医学 | 47196篇 |
外国民族医学 | 268篇 |
外科学 | 179977篇 |
综合类 | 26050篇 |
一般理论 | 581篇 |
预防医学 | 105226篇 |
眼科学 | 28371篇 |
药学 | 93397篇 |
6篇 | |
中国医学 | 1964篇 |
肿瘤学 | 70310篇 |
2018年 | 13680篇 |
2017年 | 10525篇 |
2016年 | 11451篇 |
2015年 | 13250篇 |
2014年 | 18382篇 |
2013年 | 28060篇 |
2012年 | 38496篇 |
2011年 | 40950篇 |
2010年 | 23483篇 |
2009年 | 22719篇 |
2008年 | 38567篇 |
2007年 | 41339篇 |
2006年 | 40881篇 |
2005年 | 40009篇 |
2004年 | 38461篇 |
2003年 | 36664篇 |
2002年 | 35594篇 |
2001年 | 56219篇 |
2000年 | 57233篇 |
1999年 | 48085篇 |
1998年 | 12669篇 |
1997年 | 11464篇 |
1996年 | 11868篇 |
1995年 | 11973篇 |
1994年 | 11169篇 |
1993年 | 10434篇 |
1992年 | 38371篇 |
1991年 | 37901篇 |
1990年 | 36655篇 |
1989年 | 35453篇 |
1988年 | 32847篇 |
1987年 | 32190篇 |
1986年 | 30704篇 |
1985年 | 28939篇 |
1984年 | 22052篇 |
1983年 | 19256篇 |
1982年 | 11431篇 |
1981年 | 10348篇 |
1979年 | 21020篇 |
1978年 | 15474篇 |
1977年 | 12789篇 |
1976年 | 11826篇 |
1975年 | 12818篇 |
1974年 | 15603篇 |
1973年 | 15393篇 |
1972年 | 14548篇 |
1971年 | 13584篇 |
1970年 | 12810篇 |
1969年 | 12079篇 |
1968年 | 11263篇 |
Vaccination prevents severe morbidity and mortality from COVID-19 in the general population. The immunogenicity and efficacy of SARS-CoV-2 vaccines in patients with antibody deficiency is poorly understood.
ObjectivesCOVID-19 in patients with antibody deficiency (COV-AD) is a multi-site UK study that aims to determine the immune response to SARS-CoV-2 infection and vaccination in patients with primary or secondary antibody deficiency, a population that suffers from severe and recurrent infection and does not respond well to vaccination.
MethodsIndividuals on immunoglobulin replacement therapy or with an IgG less than 4 g/L receiving antibiotic prophylaxis were recruited from April 2021. Serological and cellular responses were determined using ELISA, live-virus neutralisation and interferon gamma release assays. SARS-CoV-2 infection and clearance were determined by PCR from serial nasopharyngeal swabs.
ResultsA total of 5.6% (n?=?320) of the cohort reported prior SARS-CoV-2 infection, but only 0.3% remained PCR positive on study entry. Seropositivity, following two doses of SARS-CoV-2 vaccination, was 54.8% (n?=?168) compared with 100% of healthy controls (n?=?205). The magnitude of the antibody response and its neutralising capacity were both significantly reduced compared to controls. Participants vaccinated with the Pfizer/BioNTech vaccine were more likely to be seropositive (65.7% vs. 48.0%, p?=?0.03) and have higher antibody levels compared with the AstraZeneca vaccine (IgGAM ratio 3.73 vs. 2.39, p?=?0.0003). T cell responses post vaccination was demonstrable in 46.2% of participants and were associated with better antibody responses but there was no difference between the two vaccines. Eleven vaccine-breakthrough infections have occurred to date, 10 of them in recipients of the AstraZeneca vaccine.
ConclusionSARS-CoV-2 vaccines demonstrate reduced immunogenicity in patients with antibody deficiency with evidence of vaccine breakthrough infection.
相似文献